Menu Search
Equities

Roche Holding AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RHO6:STU

Roche Holding AG

Actions
  • Price (EUR)48.60
  • Today's Change0.20 / 0.41%
  • Shares traded0.00
  • 1 Year change+28.31%
  • Beta0.4384
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in USD (TTM)79.07bn
  • Net income in USD16.56bn
  • Incorporated1966
  • Employees112.77k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
  • Phone+41 616881111
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ROG:SWX since
announced		Transaction
value
89bio IncDeal completed18 Sep 202518 Sep 2025Deal completed36.87%3.19bn
Data delayed at least 15 minutes, as of Feb 06 2026 16:39 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.